STRADB (STE20 related adaptor beta) is a pseudokinase that functions as a regulatory component of the LKB1 signaling axis. According to UniProt annotations, STRADB forms a complex with CAB39/MO25 scaffolding proteins and acts as a pseudosubstrate that binds and activates the serine/threonine kinase STK11/LKB1, promoting its conformational transition to an active state. The gene localizes to multiple cellular compartments including the cytoplasm, cytosol, nucleus, and nucleoplasm, where it participates in protein kinase activation and phosphorylation cascades. Regarding disease relevance, STRADB expression is downregulated in response to acute psychological stress 1, suggesting potential involvement in stress-response mechanisms. Additionally, STRADB is downregulated following boron compound treatment in ovarian cancer cells, where it is functionally linked to the dysregulated PI3K/Akt/mTOR pathway commonly altered in this malignancy 2. In lung fibroblasts, STRADB was identified as a target of miR-455-3p, a microRNA modulated by transforming growth factor-beta signaling implicated in lung disease pathogenesis 3. These findings position STRADB within metabolically and developmentally critical signaling networks. However, STRADB was evaluated and excluded as a causative gene for juvenile amyotrophic lateral sclerosis 4, indicating it does not harbor disease-causing mutations in that condition.